Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

SGLT-2 inhibitors market to hit $32.16B by 2033, fueled by rising diabetes, CKD & heart failure cases; USA & Japan drive regional growth. The SGLT-2 inhibitors market will grow from US$ 17.95B in ...

A new study published in the Journal of American Medical Association showed that the usage of sodium-glucose cotransporter 2 ...

In elderly patients 65 years of age or older with heart failure with reduced ejection fraction (HFrEF), regular use of sodium ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

Even in heart attack patients with poor kidney function, researchers found SGLT2 inhibitors reduced heart failure complications.

In addition newer drugs like SGLT2 inhibitors, Angiotensin receptor neprisilyn inhibitors ,beta, blockers ,mineralocorticoid ...

Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis ...